Business Information
The group's principal activities are the research and development of small molecular therapeutics based on its activated checkpoint therapy (sm) platform. The act technology develops small molecule compounds that selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints that are defective in cancer cells. The trademarks include arqule, directed array, mapping array, amap, arqule reactor, compass array, custom array, mapmaker, optimal chemical entities, oces, parallel track, and prepqule. The group continues to advance the drug discovery efforts of pharmaceutical collaborators by providing high quality library design and compound production, including collaborations with pfizer inc, sankyo company ltd and novartis biomedical research institute. On 08-Sep-2003, the group acquired cyclis pharmaceuticals inc.
|
|
Name |
Title
|
Email
|
| Patrick Zenner | Chmn. | Available | | Nigel Rulewski | Chief Medical Officer | Available | | Richard Woodrich | Acting CFO, Treasurer | Available | | Anthony Messina | VP - Human Development | Available | | Peter Lawrence | Exec. VP, General Counsel, Chief Business Officer | Available
|
|
|
Year |
Sales |
Net Income |
| 2006 | 6,626 | (31,440) | | 2005 | 52,924 | (7,520) | | 2004 | 54,455 | (4,921)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
